Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $6.0000 (-2.6%) ($5.6500 - $6.9300) on Mon. Jul. 20, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.87% (three month average) | RSI | 81 | Latest Price | $6.0000(-2.6%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV advances 9% a day on average for past five trading days. | Weekly Trend | VBIV advances 33.5% a week on average for past two weeks. | Market Behavior | Rotation from value to growth for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) ACES(66%) UNG(32%) SIL(27%) XBI(72%) VWO(10%) | Factors Impacting VBIV price | VBIV will decline at least -4.435% in a week (0% probabilities). IPO(-21%) GDXJ(44%) GDX(55%) IBUY(-6%) EEM(18%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -4.435% (StdDev 8.87%) | Hourly BBV | 1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.31(12.99%) | 10 Day Moving Average | $4.67(28.48%) | 20 Day Moving Average | $3.82(57.07%) | To recent high | -2.6% | To recent low | 19.9% | Market Cap | $1.384b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |